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Neurotransmitters are a group of chemical messengers that enable
communication between the neurons in the synaptic cleft. With regard
to chemical properties, neurotransmitters can be grouped into amino
acids (including glutamate, glycine, serine and gamma aminobutyric
acid), peptides, purines, andmonoamines or biogenic amines (including
acetylcholine, epinephrine, norepinephrine, dopamine and serotonin).
Most neurotransmitters have either excitatory or inhibitory effects,
but only a few can exert both depending upon the type of receptors
that are present [13]. After biosynthesis neurotransmitters are stored
within synaptic vesicles and secreted in response to the appropriate
nerve impulse [13]. Peptides have higher molecular weight than bio-
genic amines and amino acids, and are produced and released by
neurons through the regulated secretory route. Interestingly, many
peptides exhibit neurotransmitter activity as well as possess hormonal
function.
Inborn errors of neurotransmitter biosynthesis, breakdown or trans-
port are a group of very rare neurometabolic diseases. The incidence of
the combined neurotransmitter diseases can only be estimated, but so
far around 1500 patients have been published worldwide [3,12,19,21,
28]. Clinical symptoms can appear at any age from newborn to adult-
hood. In the following the different groups of neurotransmitter disor-
ders and their main features are described:
Disorders of monoamines and tetrahydrobiopterin metabolism.
Tetrahydrobiopterin (BH4) is known to be the natural cofactor for
phenylalanine hydroxylase (PAH), tyrosine hydroxylase (TH), and tryp-
tophan hydroxylase (TPH) as well as all three isoforms of nitric oxide
synthase (NOS) [27]. The BH4 dependent enzymes TH and TPH are to-
gether with the aromatic amino acid decarboxylase (AADC) the key en-
zymes in the biosynthesis of the neurotransmitters dopamine and
serotonin [1]. Accordingly, disorders of BH4 metabolism result in defi-
ciency of biogenic amines. In addition to enzyme deficiencies, two
transporter defects are known to cause disorders of biogenic amineme-
tabolism [16,23]. The relevant enzymes and transporters are listed in
Table 1. The clinical presentation is determined by the type and severityTable 1
Overview on inborn errors of neurotransmitter metabolism included in the iNTD patient
registry, including acronym and OMIM number (Online Mendelian Inheritance in Man).
Disease name Acronym
Gene
name OMIM#
Aromatic L-amino acid decarboxylase
deficiency
AADCD DDC #608643
Tyrosine hydroxylase deficiency THD TH #191290
Dopamine β-hydroxylase deficiency DßHD DßH #223360
Monoamine oxidase A deficiency MOAAD MAO-A # 309850
Dopamine transporter deficiency DATD SLC6A3 #126455
Vesicular monoamine transporter deficiency VMATD SLC18A2 #193001
Autosomal recessive GTP-cyclohydrolase
deficiency
ARGTPCHD GCH1 #233910
Autosomal dominant GTP-cyclohydrolase
deficiency
ADGTPCHD GCH1 #600225
6-Pyruvoyl-tetrahydropterin synthase
deficiency
PTPSD PTS #261640
Dihydropteridine reductase deficiency DHPRD QDPR #261630
Sepiapterin reductase deficiency SRD SPR #182125
Folate receptor alpha deficiency FOLR1D FOLR1 # 613068
Dihydrofolate reductase deficiency DHFRD DHFR # 613839
3-Phosphoglycerat dehydrogenase
deficiency
3-PGDHD PHGDH #606879
3-Phosphoserine phosphatase deficiency 3-PSPD PSPH #172480
Phosphoserine aminotransferase deficiency PSATD PSAT1 #610936
Nonketotic hyperglycinemia NKH AMT
GLDC
GCSH
T#238310
P#238300
H#238330
GABA-transaminase deficiency GABATD ABAT #137150
Succinate semialdehyde dehydroxylase
deficiency
SSADHD ALDH5A1 #271980of the underlying disorder [18] and ranges from intermittent focal dys-
tonia and dystonia-parkinsonism to severe, lethal infantile encephalop-
athies. In adulthood these diseases may cause behavioral and mood
disorders [11,20,25]. Patients with disorders of BH4 metabolism can
with two exceptions be identified by detection of hyperphenylalanin-
emia on newborn screening (PKU), thereby allowing early diagnosis
and initiation of treatment in asymptomatic individuals.
1.1. Folates
Folates play an essential role in central one-carbon methyl transfer
reactions, mediating several biological processes including synthesis of
neurotransmitters. 5-MTHF is the widely distributed form in the blood-
stream. The autosomal recessive inherited folate receptor alpha
(FOLR1) deficiency leads to impaired transport of folate to the CNS
resulting in psychomotor decline, progressive movement disturbance,
white matter disease, and epilepsy [5,24]. Patients with dihydrofolate
reductase deficiency (DHFR) present with megaloblastic anemia, cere-
bral folate deficiency and a variety of neurological manifestations,
which respond at least partly to treatment with folinic acid [6].
1.2. Disorders of GABA metabolism
Two disorders of GABA catabolism are known: Succinic semialde-
hyde dehydrogenase (SSADH) and GABA-transaminase deficiency.
Most patients with SSADH deficiency develop symptoms in the first
2 years of life and present with prominent deficits in expressive
language, motor delay, hypotonia, non-progressive ataxia, epilepsy
and neuropsychiatric symptoms [10,22]. Two families with GABA-
transaminase deficiency have been reported displaying developmental
delay and hypotonia in early childhood and severe expressive language
impairment and obsessive-compulsive disorder in adolescence and
adulthood as well as ataxia and hyporeflexia [14,26].
1.3. Disorders of serine metabolism
Defects of serine metabolism encompass phosphoglycerate dehy-
drogenase deficiency, phosphoserine aminotransferase deficiency, and
3-phosphoserine phosphatase deficiency. Patients with phosphoglycer-
ate dehydrogenase or phosphoserine aminotransferase manifest with
severe intellectual disability, spastic tetraparesis, severe microcephaly
and epilepsy [8]. A deficiency of 3-phosphoserine phosphatase was
identified in one patient with moderate intellectual disability who also
had Williams's syndrome [15] and in another patient with intrauterine
growth restriction, intellectual disability, childhood onset epilepsy, and
borderline microcephaly who developed progressive lower extremity
hypertonia, axonal neuropathy, and hand contractures in adulthood [4].
1.4. Disorders of glycine breakdown
A deficiency of the activity of the glycine cleavage enzyme system
leads to nonketotic hyperglycinemia (NKH) due to an accumulation of
glycine in tissues and the central nervous system. Based on the amount
of residual activity resulting from the particular mutation, clinical pre-
sentation of NKH ranges from severe neonatal hypotonia, failure to
thrive and burst suppression pattern on EEG in the severe form, to
mild mental retardation, learning disabilities or even normal intelli-
gence in the mild from [7,12].
All neurotransmitter related disorders are rare, and consequently,
patients are scattered around the world and frequently do not have ac-
cess to medical care at centers of expertise. Furthermore, evidence base
of current diagnostic and therapeutic approaches is extremely limited
and current diagnostic and treatment strategies vary enormously
between centers, resulting in sub-optimal care for individual
patients. It can be expected that these inequalities have a negative
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other rare diseases [2,17].
The major aims of the International Working Group on Neurotrans-
mitter related Disorders (iNTD) are to establish the first network and
patient registry for neurotransmitter related disorders. The patient reg-
istry will enable detailed analysis of the natural courses of the diseases,
the diagnostic approaches and the current therapy strategies as well as
the quality of life of the affected patients and possible genotype/
phenotype-correlations. Besides expanding knowledge about these dis-
eases, iNTD will enable the development of the first evidence-based
consensus guidelines for patients with various neurotransmitter related
disorders.
This paper describes the establishment of iNTD and major achieve-
ments within the first 2 years of the project.2. Methods
2.1. The iNTD network
In 2013 the initiative “International Working Group on Neurotrans-
mitter Related Disorders (iNTD)”was founded by threemedical experts
from the University Hospital Heidelberg (Germany), the Hospital Sant
Joan de Déu in Barcelona (Spain) and the Great Ormond Street Hospital
in London (United Kingdom) with the aim to foster scientific and clini-
cal networking on an international level and, ultimately, to promote
health care for patients with neurotransmitter related disorders. Since
then the network has continued to grow and today iNTD consists of
43 project partners from 24 countries worldwide (Fig. 1 and supple-
ment 1). iNTD launched a network website (www.intd-online.org),
where network information and activities are announced. Furthermore,
the website provides disease related information for families and care-
takers as well as health professionals. The steering committee consists
of Thomas Opladen (University Hospital Heidelberg), Àngels Garcia-
Cazorla (Hospital Sant Joan de Déu Barcelona) and Manju Kurian
(Great Ormond Street Hospital London). The steering committee has
the overall responsibility to ensure satisfactory progress of the network.
It specifies and defines the organization, management, responsibilities
and tasks of the network. All iNTD networkmembers that are contribut-
ing to the registry have signed a consortium agreement.AADC (24) 
25% 
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1% 
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Fig. 1. Total number, frequency and distribution of neurotransmitter deficiencies in the
iNTD patient registry.2.2. The patient registry
Within one working group iNTD set up the first international, longi-
tudinal patient registry for neurotransmitter related disorders. The pa-
tient registry is web-based and password-protected (https://intd-
registry.org). It was approved by the local ethics committee of the Uni-
versity Hospital Heidelberg (coordinating center, application number S-
471/2014) on 22th December 2014. The data are managed on a secure
server, hosted by University Hospital Heidelberg, the site responsible
for data storage and processing. The previously existing, stand-alone
registries for BH4 and AADC deficiencies, BIODEF and JAKE, established
and hosted at the University Children's Hospital in Zürich, Switzerland
by Prof. Nenad Blau, have ceased collection of new patient data. To pre-
serve the highly valuable historical data contained in BIODEF and JAKE,
the iNTD registry will collaborate with both registries to transfer
existing data into the iNTD registry after obtaining informed consent
of the respective patients, parents or legal representatives.
Patients' data is collected after written informed consent is obtained
by physicians at each participating iNTD center. After a baseline visit,
longitudinal follow-up visits are performed annually. Initially only dis-
orders of biogenic amine metabolism, BH4 deficiencies and cerebral fo-
late deficiencies were included. In January 2016 the registry was
extended to amino acid neurotransmitter diseases including the serine
synthesis deficiencies, disorders of glycine metabolism and GABA relat-
ed disorders (listed in Table 1). At the same time we also began to reg-
ister patients with abnormal CSF results suggesting a neurotransmitter
disorder but without known diagnosis, for further research purposes.
3. Results
iNTD aims for worldwide coverage. At the time of publication, the
iNTD network included 43 partners from 3 continents and 24 different
countries (for details see list of iNTD network partners in the supple-
ment). At present, 21 clinical partners have met all necessary legal re-
quirements and are contributing data to the registry. The approval of
further study centers is in process and will follow. Since data collection
began in January 2015, the number of patients is steadily growing. As of
30 June 2015, 95 patients with a confirmed diagnosis of neurotransmit-
ter related disorders have been registered. In total 95 baseline visits and
33 follow up visits have been documented in the registry so far.
Patients with AADC deficiency are so far the most frequent popula-
tion in the registry (n = 24, 25%), followed by PTPS deficiency (n =
22, 23%) and autosomal dominant GTPCH deficiency (n= 12, 13%; de-
tails in Fig. 1). The predominance of AADC deficiency is partly explained
by the support of the AADC parent organization (AADC Research Trust;
www.aadcresearch.org) which promoted the study within their mem-
bership. There are few patients with disorders of amino acid neuro-
transmitter metabolism as a result of their very recent inclusion in the
registry. At present there are no patients with folate disorders included.
The median age of patients in the database is 10.3 years (range: 3
months to 42.5 years). Of note, 25 patients (26.3%) in the registry are
older than 16 years (Table 2). It is obvious that with a growing adult co-
hort, newmedical and social care aspects including behavioral aswell as
psychological problems, puberty and integration into the social life and
work systems will arise. First epidemiological results confirm the
discrepancy between age of symptom onset and age at diagnosis for
some disorders (Fig. 2).
3.1. Guideline development
In neurotransmitter related disorders clinical symptoms can be non-
specific and diagnosis is often delayed depending significantly on the
personal experience of the treating physician. As a consequence, pa-
tients and their parents often traverse a stressful odyssey from doctor
to doctor with frequent misdiagnoses, such as cerebral palsy, myasthe-
nia gravis or seizure disorders [9,19] before the correct diagnosis is
Table 2
Current number, gender distribution, age range, age at first symptoms and age at diagnosis of 95 patients included in the iNTD registry. m = male; f = female.
Disease name Number and gender of patients Age range Age range at first symptoms (median) Age range at diagnosis (median)
AADC deficiency 24 (5 m/19f) 8.0 months–36.0 years 1st month of life–5.0 months
(2.5 months)
4.9 months–32.0 years
(9.8 months)
TH deficiency 11 (3 m/8f) 3.0 years–35.6 years 1st month of life–5.0 months
(3.0 months)
5.5 months–30.0 years
(2.8 years)
MAOA deficiency 1 (1 m/0f) 4.5 years 6.0 months 21.6 months
ARGTPCH deficiency 4 (4 m/0f) 4.0 years–32.7 years 1st month of life–48.0 years
(13.8 months)
5.9 months–6.0 years
(1.4 years)
ADGTPCH deficiency 12 (3 m/9f) 3.8 years–41.8 years 6.0 months–9.0 years
(44.1 months)
1.5 years–36.0 years
(7.0 years)
PTPS deficiency 22 (9 m/13f) 2.0 years–42.5 years 1st month of life–1.5 years
(3.8 months)
0.1 months–7.8 years
(1.0 month)
DHPR deficiency 11 (5 m/6f) 3.0 months–26.3 years 1st month of life–2.0 years
(8.0 months)
0.1 months–2.8 years
(6.9 month)
SR deficiency 2 (1 m/1f) 3.7 years–8.6 years 6.0 months
(6.0 months)
6.9 months−.6 years
(3.6 years)
3-PGDH deficiency 1 (1 m/0f) 8.9 years 1st month of life 4.9 months
NKH 4 (2 m/2f) 5.2 years–17.9 years 1st month of life–3.0 years
(9.8 months)
0.1 months–5.0 years
(2.4 months)
SSADH deficiency 4 (2 m/2f) 1.2 years–10.5 years 2.0 months–.5 years
(10.3 months)
2.9 years–10.8 years
(4.0 years)
Total 95 (36 m/59f) 3.0 months–42.5 years 1st month of life–9.0 years
(3.0 months)
0.1 months–36.0 years
(1.1 years)
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ible worsening of the patient's condition and result in significant costs
for the health care system. Since evidence-based guidelines for diagno-
sis and treatment do not exist for any of these disorders, one working
group of iNTD is focused upon the development of evidence based
guidelines for the most frequent neurotransmitter disorders. The evi-
dence base will be derived from a systematic literature search and
review, in addition to data from the patient registry. Relevant publica-
tions will be identified and evaluated using a standardized procedure
in analogy to the methodology of SIGN (Scottish Intercollegiate Guide-
line Network; www.sign.ac.uk) and GRADE (Grading of Recommenda-
tions Assessment, Development and Evaluation Working Group). In
the following, evidence-based recommendations will be formulated
for diagnostic procedures, therapeutic strategies, and follow-up moni-
toring. The guidelines will be published in peer reviewed journals.
The first guidelines developed by iNTD were for the diagnosis and
treatment of AADC deficiency (Wassenberg T, Orphanet J Rare Dis,
2016, in press). The guideline working group consisted of 13 child neu-
rologists, 5 biochemists and 1 research project manager from several
European countries, the USA and Taiwan. All group members are affili-
ated with iNTD and are experienced in the diagnosis and treatment of
AADC deficiency. Furthermore, a representative of the European AADC
parental organization participated in guideline development). The de-
velopment of evidence based guidelines for inborn errors of BH4 disor-
ders will follow in near future as the next iNTD guideline.
4. Discussion
In developed countries, where infant mortality caused by infectious
diseases is low, research on rare diseases has a very high priority as stat-
ed in the European Commission's Communication on Rare Diseases:
“Coordination projects aimed at an optimal use of the limited resources
dedicated to research on rare diseases should be encouraged” (Source:
Communication from the commission to the European Parliament, the
Council, the European Economic and Social Committee of the Regions,
11. November 2008).
Because inherited neurotransmitter related disorders are very rare,
significant progress can only be achieved by transnational efforts. For
that purpose, an international network and registry for rare neurotrans-
mitter related disorders are indispensable to improve the knowledge
base, develop international consensus care guidelines, and foster net-
working on international level and, ultimately, to promote health carefor patients with neurotransmitter related disorders. Additionally,
since many of these disorders are amenable to treatment, promoting
awareness and knowledge among the medical community is a matter
of great importance.
In the last 2 years, iNTD has established the first worldwide network
of experts for neurotransmitter related disorders. The iNTD network
provides a platform for clinicians and scientists to exchange expertise
and to improve international collaborations regarding these rare neuro-
transmitter related diseases. Currently iNTD includes 43 metabolic cen-
ters from 24 countries worldwide and is open for collaboration with
additional stakeholders. iNTD seeks to build partnerships between sci-
entists and non-governmental parent organizations with longstanding
basic research, diagnostic and clinical activities. The consortium aims
to mobilize a critical mass of expertise and patient numbers to enable
rapid translation of basic research into clinical studies at the patient's
bedside.
The iNTD registry study is the first detailed longitudinal study in the
field of neurotransmitter disorders. To enable systematic and standard-
ized collection of data, all patient data entered into the registry are sur-
veyed by medical doctors. The successful initiation of the registry in
January 2015 and the constantly growing number of registered patients
will enable detailed clinical phenotyping of the diseases for the first
time, and interdisciplinary analysis of the natural history, diagnostic ap-
proaches and current treatment strategies, genotype/phenotype corre-
lation, as well as the quality of life of affected patients.
4.1. Outlook
Within the last 2 years iNTD has developed a stable framework for
exchange in clinical and scientific research. In future iNTD aims to fur-
ther improve the awareness and knowledge on rare neurotransmitter
related disorders by providing clinical and scientific information to
patients and health care professionals. The iNTD registry seeks the in-
clusion of more than 250 patients in the registry by extending coopera-
tion with other expert centers. The long term focus will be on the
evaluation of disease natural history, specifically in the context of up-
coming new treatment options. As one example Dr. Toni Pearson
(Washington University in St Louis, USA) developed a highly detailed
parent questionnaire for patientswith AADC deficiencywhich evaluates
the natural course, in the context of the upcoming gene therapy trials
for AADC deficiency in the USA and England. Thanks to the modular IT
system the extension of the iNTD patient registry and the inclusion of
Fig. 2.Age atfirst symptoms versus age at diagnosis in 95 patientswith different neurotransmitter disorders (Boxplotwithmedian, quartiles, outliers (caseswith values between 1.5 and 3
box lengths from the upper or lower edge of the interquartile range) and extremes (cases with values more than 3 box lengths from the upper or lower edge of the interquartile range).
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Hereby a standardized clinical and biochemical characterization of the
new disorder and a direct comparisons with known disorders will be
easily possible.
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